According to the new market research report Liquid Biopsy Market
by Product (Assay Kits, Instruments, Service), Circulating Biomarkers
(CTC, ctDNA), Technology (NGS, PCR), Application (Cancer (Lung, Breast,
Prostate), Non-Cancer), End User (Reference Lab, Hospitals) – Global
Forecast to 2026, published by MarketsandMarkets™, the global market is
projected to reach USD 5.8 billion by 2026 from USD 2.5 billion in 2021,
at a CAGR of 18.1%.
Browse in-depth TOC on “Liquid Biopsy Market”
152 – Tables
50 – Figures
231 – Pages
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350
The
rising incidence and prevalence of cancer and the increasing preference
for noninvasive treatment procedures are among the major factors
propelling the growth of this market. Emerging economies such as China,
Japan, and India are providing lucrative opportunities for the players
operating in the market.
The assay kits segment accounted for the largest share of the liquid biopsy market, by product & service segment, in 2020
Based
on product & service, the market is segmented into assay kits,
instruments, and services. The assay kits segment accounted for the
largest share of the liquid biopsy market in 2020. The standard purchase
requirement of assay kits makes them a recurrent cost which is a key
factor boosting the market growth of this segment.
Circulating tumor DNA (ctDNA) segment to register the highest growth rate during the forecast period
The
liquid biopsy market is segmented into circulating tumor cells,
circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular
vesicles (EVS), and other circulating biomarkers. The circulating tumor
DNA (ctDNA) segment is expected to grow at the highest CAGR during the
forecast period. The superiority of ctDNA to previous plasma biomarkers
in sensitivity and clinical correlations is a major factor driving its
growth.
The reference laboratories segment accounted for the largest share of the liquid biopsy, by end user segment, in 2020
Based
on end users, the liquid biopsy market has been segmented into
reference laboratories, hospitals and physician laboratories, academic
& research centers, and other end users. In 2020, the reference
laboratories segment accounted for the largest share of the market. The
increasing outsourcing of liquid biopsy tests to reference laboratories
is driving this segments growth.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=13966350
North America is the largest regional market for liquid biopsy market
The
global market has been segmented into four major regions North America,
Europe, the Asia Pacific, and the Rest of the World. In 2020, North
America accounted for the largest share of the market. The large share
of this region can be attributed to the highly developed healthcare
systems in the US and Canada, increasing prevalence of cancer, and
presence of many leading national clinical laboratories.
The
major players operating in this liquid biopsy market are F. Hoffmann-La
Roche Ltd. (Switzerland), Myriad Genetics, Inc. (US), QIAGEN N.V.
(Netherlands), Thermo Fisher Scientific, Inc. (US), Guardant Health,
Inc. (US), MDxHealth SA (Belgium), Exact Sciences Corporation (US),
Illumina Inc. (US), Sysmex Inostics (US), Bio-Rad Laboratories, Inc.
(US), Biocept, Inc. (US), NeoGenomics, Inc. (US), ANGLE plc (UK),
Menarini-Silicon Biosystems (Italy), Vortex Biosciences, Inc. (US),
Exosome Diagnostics, Inc. (US), Agena Bioscience, Inc. (US), MedGenome
Inc. (US), Epigenomics AG (Germany), and Personal Genome Diagnostics,
Inc. (US).
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/liquid-biopsy-market.asp
Content Source: https://www.marketsandmarkets.com/PressReleases/liquid-biopsy.asp